SK281078B6 - Použitie polymérnej živice na mletie liečivej látky alebo diagnostického činidla - Google Patents

Použitie polymérnej živice na mletie liečivej látky alebo diagnostického činidla Download PDF

Info

Publication number: SK281078B6
Authority: SK; Slovakia
Prior art keywords: grinding; particles; particle size; polymeric resin; drug substance
Prior art date: 1992-11-25

Application number

SK1301-93A

Other languages

English (en)

Slovak (sk)

Other versions

SK130193A3 (en

Inventor

Joseph A. Bruno

Brian D. Doty

Evan Gustow

Kathleen J. Illig

Natarajan Rajagopalan

Pramod Sarpotdar

Original Assignee

Nanosystems L. L. C.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-25

Filing date

1993-11-19

Publication date

2000-11-07

1993-11-19 Application filed by Nanosystems L. L. C. filed Critical Nanosystems L. L. C.

1994-09-07 Publication of SK130193A3 publication Critical patent/SK130193A3/sk

2000-11-07 Publication of SK281078B6 publication Critical patent/SK281078B6/sk

Links

238000000227 grinding Methods 0.000 title claims abstract description 57
239000002952 polymeric resin Substances 0.000 title claims abstract description 16
229920003002 synthetic resin Polymers 0.000 title claims abstract description 16
239000000032 diagnostic agent Substances 0.000 title claims abstract description 7
229940039227 diagnostic agent Drugs 0.000 title claims abstract description 7
239000000126 substance Substances 0.000 title abstract description 6
238000000576 coating method Methods 0.000 claims abstract description 11
238000001238 wet grinding Methods 0.000 claims abstract description 11
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims abstract description 10
239000004793 Polystyrene Substances 0.000 claims abstract description 10
229920002223 polystyrene Polymers 0.000 claims abstract description 10
229920000515 polycarbonate Polymers 0.000 claims abstract description 8
239000004417 polycarbonate Substances 0.000 claims abstract description 8
239000012798 spherical particle Substances 0.000 claims abstract description 5
239000011248 coating agent Substances 0.000 claims description 10
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 7
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 7
229960002009 naproxen Drugs 0.000 claims description 7
OBISGMNJKBVZBT-UHFFFAOYSA-N ethyl 3,5-diacetamido-2,4,6-triiodobenzoate Chemical compound CCOC(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I OBISGMNJKBVZBT-UHFFFAOYSA-N 0.000 claims description 6
239000013543 active substance Substances 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 2
238000003384 imaging method Methods 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
239000002245 particle Substances 0.000 abstract description 46
229940088679 drug related substance Drugs 0.000 abstract description 20
239000008186 active pharmaceutical agent Substances 0.000 abstract description 18
238000000034 method Methods 0.000 abstract description 18
238000011109 contamination Methods 0.000 abstract description 17
239000012216 imaging agent Substances 0.000 abstract description 7
229920005989 resin Polymers 0.000 abstract description 4
239000011347 resin Substances 0.000 abstract description 4
238000002059 diagnostic imaging Methods 0.000 abstract description 3
238000009837 dry grinding Methods 0.000 abstract description 3
230000001747 exhibiting effect Effects 0.000 abstract 1
239000002609 medium Substances 0.000 description 21
239000006185 dispersion Substances 0.000 description 15
239000011324 bead Substances 0.000 description 12
239000011162 core material Substances 0.000 description 12
239000007788 liquid Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000002845 discoloration Methods 0.000 description 7
238000003801 milling Methods 0.000 description 7
229910001220 stainless steel Inorganic materials 0.000 description 7
239000010935 stainless steel Substances 0.000 description 7
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
239000011521 glass Substances 0.000 description 6
-1 zirconium silicates Chemical class 0.000 description 6
239000003814 drug Substances 0.000 description 5
239000003607 modifier Substances 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
239000002612 dispersion medium Substances 0.000 description 4
125000004494 ethyl ester group Chemical group 0.000 description 4
230000005484 gravity Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 4
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
229910052804 chromium Inorganic materials 0.000 description 3
239000011651 chromium Substances 0.000 description 3
239000002872 contrast media Substances 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 3
229910052742 iron Inorganic materials 0.000 description 3
239000000463 material Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
238000003892 spreading Methods 0.000 description 3
229910052726 zirconium Inorganic materials 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
208000034809 Product contamination Diseases 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
229910052788 barium Inorganic materials 0.000 description 2
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
238000010951 particle size reduction Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
229910052727 yttrium Inorganic materials 0.000 description 2
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
229910001928 zirconium oxide Inorganic materials 0.000 description 2
NRZZLYODXDSLEK-UHFFFAOYSA-N (6-ethoxy-6-oxohexyl) 3,5-diacetamido-2,4,6-triiodobenzoate Chemical compound CCOC(=O)CCCCCOC(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I NRZZLYODXDSLEK-UHFFFAOYSA-N 0.000 description 1
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
229920004943 Delrin® Polymers 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
238000010923 batch production Methods 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229940039231 contrast media Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229910052735 hafnium Inorganic materials 0.000 description 1
VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000010316 high energy milling Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
239000000178 monomer Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
238000007788 roughening Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000004576 sand Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229920005573 silicon-containing polymer Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229910000859 α-Fe Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C1/00—Photosensitive materials
- G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/90—Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/928—X-ray agent

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Materials Engineering (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cephalosporin Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Disintegrating Or Milling (AREA)
Crushing And Grinding (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

SK1301-93A 1992-11-25 1993-11-19 Použitie polymérnej živice na mletie liečivej látky alebo diagnostického činidla SK281078B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US98163992A	1992-11-25	1992-11-25

Publications (2)

Publication Number	Publication Date
SK130193A3 SK130193A3 (en)	1994-09-07
SK281078B6 true SK281078B6 (sk)	2000-11-07

Family

ID=25528539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1301-93A SK281078B6 (sk)	1992-11-25	1993-11-19	Použitie polymérnej živice na mletie liečivej látky alebo diagnostického činidla

Country Status (24)

Country	Link
US (1)	US5518187A (de)
EP (1)	EP0600528B1 (de)
JP (2)	JPH06209982A (de)
KR (1)	KR100312798B1 (de)
AT (1)	ATE193646T1 (de)
AU (1)	AU660852B2 (de)
CA (1)	CA2107400C (de)
CZ (1)	CZ284802B6 (de)
DE (1)	DE69328815T2 (de)
DK (1)	DK0600528T3 (de)
ES (1)	ES2148198T3 (de)
FI (1)	FI108399B (de)
GR (1)	GR3034227T3 (de)
HU (1)	HU210928B (de)
IL (1)	IL107191A0 (de)
MX (1)	MX9306443A (de)
MY (1)	MY109419A (de)
NO (1)	NO933719L (de)
NZ (1)	NZ248813A (de)
PH (1)	PH31118A (de)
PT (1)	PT600528E (de)
RU (1)	RU2122405C1 (de)
SK (1)	SK281078B6 (de)
TW (1)	TW239075B (de)

Families Citing this family (301)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5478705A (en) *	1994-05-25	1995-12-26	Eastman Kodak Company	Milling a compound useful in imaging elements using polymeric milling media
US5718388A (en) *	1994-05-25	1998-02-17	Eastman Kodak	Continuous method of grinding pharmaceutical substances
US5500331A (en) *	1994-05-25	1996-03-19	Eastman Kodak Company	Comminution with small particle milling media
US5513803A (en) *	1994-05-25	1996-05-07	Eastman Kodak Company	Continuous media recirculation milling process
DE69527266T2 (de) *	1994-07-26	2003-03-06	Sony Corp., Tokio/Tokyo	Verfahren zur bildübertragung
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JP4484247B2 (ja) *	1995-02-24	2010-06-16	エランファーマインターナショナル，リミティド	ナノ粒子分散体を含有するエアロゾル
US5474237A (en) *	1995-02-28	1995-12-12	Eastman Kodak Company	Method and apparatus for eliminating screen plugging in wet grinding mills
US5834025A (en) *	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5662279A (en) *	1995-12-05	1997-09-02	Eastman Kodak Company	Process for milling and media separation
US20050267302A1 (en) *	1995-12-11	2005-12-01	G.D. Searle & Co.	Eplerenone crystalline form exhibiting enhanced dissolution rate
AU5719798A (en)	1996-12-31	1998-07-31	Inhale Therapeutic Systems, Inc.	Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US20030203036A1 (en) *	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) *	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
GB9703673D0 (en) *	1997-02-21	1997-04-09	Bradford Particle Design Ltd	Method and apparatus for the formation of particles
US20050004049A1 (en) *	1997-03-11	2005-01-06	Elan Pharma International Limited	Novel griseofulvin compositions
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB9726543D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel compositions
US6086242A (en) *	1998-02-27	2000-07-11	University Of Utah	Dual drive planetary mill
DE69912441T2 (de)	1998-08-19	2004-08-19	Skyepharma Canada Inc., Verdun	Injizierbare wässerige propofoldispersionen
US8236352B2 (en) *	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US20080213378A1 (en) *	1998-10-01	2008-09-04	Elan Pharma International, Ltd.	Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) *	2001-05-18	2004-01-22	Jain Rajeev A	Rapidly disintegrating solid oral dosage form
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
US20090297602A1 (en) *	1998-11-02	2009-12-03	Devane John G	Modified Release Loxoprofen Compositions
US20070160675A1 (en) *	1998-11-02	2007-07-12	Elan Corporation, Plc	Nanoparticulate and controlled release compositions comprising a cephalosporin
MXPA01004381A (es) *	1998-11-02	2005-09-08	Elan Corp Plc	Composicion de multiparticulado de liberacion modificada.
US20040141925A1 (en) *	1998-11-12	2004-07-22	Elan Pharma International Ltd.	Novel triamcinolone compositions
US6428814B1 (en)	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en)	2000-09-21	2005-11-29	Elan Pharma International Ltd.	Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
JP2000325768A (ja) *	1999-03-15	2000-11-28	Inoue Seisakusho:Kk	媒体分散方法
US7919119B2 (en) *	1999-05-27	2011-04-05	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6610317B2 (en)	1999-05-27	2003-08-26	Acusphere, Inc.	Porous paclitaxel matrices and methods of manufacture thereof
US6444223B1 (en)	1999-05-28	2002-09-03	Alkermes Controlled Therapeutics, Inc.	Method of producing submicron particles of a labile agent and use thereof
AU5300000A (en) *	1999-06-01	2000-12-18	Elan Pharma International Limited	Small-scale mill and method thereof
US20040115134A1 (en) *	1999-06-22	2004-06-17	Elan Pharma International Ltd.	Novel nifedipine compositions
US6656504B1 (en)	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
KR100793668B1 (ko) *	1999-12-08	2008-01-10	파마시아 코포레이션	강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
US20030083493A1 (en) *	1999-12-08	2003-05-01	Barton Kathleen P.	Eplerenone drug substance having high phase purity
EA008449B1 (ru) *	1999-12-08	2007-06-29	Фармация Корпорейшн	Кристаллическая форма эплеренона
JP4763957B2 (ja)	2000-05-10	2011-08-31	オバン・エナジー・リミテッド	メディアミリング
US6316029B1 (en)	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
MY120279A (en)	2000-05-26	2005-09-30	Pharmacia Corp	Use of a celecoxib composition for fast pain relief
KR100786927B1 (ko) *	2000-06-28	2007-12-17	스미스클라인비이참피이엘시이	습식 분쇄방법
PE20020146A1 (es) *	2000-07-13	2002-03-31	Upjohn Co	Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP4969761B2 (ja) *	2000-08-31	2012-07-04	オバン・エナジー・リミテッド	所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US7198795B2 (en)	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) *	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US20030224058A1 (en) *	2002-05-24	2003-12-04	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7998507B2 (en)	2000-09-21	2011-08-16	Elan Pharma International Ltd.	Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20080241070A1 (en) *	2000-09-21	2008-10-02	Elan Pharma International Ltd.	Fenofibrate dosage forms
GB0027357D0 (en) *	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
DE60140268D1 (de) *	2000-11-30	2009-12-03	Vectura Ltd	Partikel zur verwendung in einer pharmazeutischen zusammensetzung
US20030072807A1 (en) *	2000-12-22	2003-04-17	Wong Joseph Chung-Tak	Solid particulate antifungal compositions for pharmaceutical use
US6623761B2 (en)	2000-12-22	2003-09-23	Hassan Emadeldin M.	Method of making nanoparticles of substantially water insoluble materials
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) *	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) *	2000-12-22	2006-05-02	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) *	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US7193084B2 (en)	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
US9700866B2 (en) *	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
US6951656B2 (en) *	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) *	2000-12-22	2004-12-23	Mahesh Chaubal	Process for production of essentially solvent-free small particles
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US20040022862A1 (en) *	2000-12-22	2004-02-05	Kipp James E.	Method for preparing small particles
FI20010115A0 (fi) *	2001-01-18	2001-01-18	Orion Corp	Menetelmä nanopartikkelien valmistamiseksi
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
JP4223390B2 (ja)	2001-06-05	2009-02-12	エラン・ファルマ・インターナショナル・リミテッド	材料をフライス削りするシステムおよび方法
US6976647B2 (en) *	2001-06-05	2005-12-20	Elan Pharma International, Limited	System and method for milling materials
DE60203506T2 (de) *	2001-06-22	2006-02-16	Marie Lindner	Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
US7758890B2 (en)	2001-06-23	2010-07-20	Lyotropic Therapeutics, Inc.	Treatment using dantrolene
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) *	2001-09-19	2003-05-22	Elan Pharma International Limited	Nanoparticulate insulin
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003026662A1 (en) *	2001-09-25	2003-04-03	Pharmacia Corporation	Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
BR0212833A (pt) *	2001-09-26	2004-10-13	Baxter Int	Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) *	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
ES2292848T3 (es)	2001-10-12	2008-03-16	Elan Pharma International Limited	Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7112340B2 (en)	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2465793A1 (en) *	2001-11-07	2003-05-15	Taffy Williams	Methods for vascular imaging using nanoparticulate contrast agents
US20030129242A1 (en) *	2002-01-04	2003-07-10	Bosch H. William	Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) *	2002-02-04	2004-05-27	Elan Pharma International Limited	Novel benzoyl peroxide compositions
EP1471887B1 (de) *	2002-02-04	2010-04-21	Elan Pharma International Ltd.	Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
WO2003080023A2 (en) *	2002-03-20	2003-10-02	Elan Pharma International Limited	Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
WO2003077886A1 (en) *	2002-03-20	2003-09-25	Hosokawa Micron Corporation	Method of manufacturing chemical-containing composite particles
WO2003080027A1 (en) *	2002-03-20	2003-10-02	Elan Pharma International, Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
WO2003082213A2 (en) *	2002-03-28	2003-10-09	Imcor Pharmaceutical Company	Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
EP1494649B1 (de)	2002-04-12	2012-01-04	Alkermes Pharma Ireland Limited	Nanopartikuläre megestrol- formulierungen
US9101540B2 (en) *	2002-04-12	2015-08-11	Alkermes Pharma Ireland Limited	Nanoparticulate megestrol formulations
US7101576B2 (en) *	2002-04-12	2006-09-05	Elan Pharma International Limited	Nanoparticulate megestrol formulations
US20100226989A1 (en) *	2002-04-12	2010-09-09	Elan Pharma International, Limited	Nanoparticulate megestrol formulations
US20040105889A1 (en) *	2002-12-03	2004-06-03	Elan Pharma International Limited	Low viscosity liquid dosage forms
DE10218109A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
GB0216562D0 (en) *	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
ATE419835T1 (de) *	2002-05-06	2009-01-15	Elan Pharma Int Ltd	Nystatin-nanopartikelzusammensetzungen
US20070264348A1 (en) *	2002-05-24	2007-11-15	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
JP4533134B2 (ja) *	2002-06-10	2010-09-01	エランファーマインターナショナル，リミティド	ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
EP2283864A1 (de)	2002-07-16	2011-02-16	Elan Pharma International Ltd.	Flüssige Zusammensetzung enthaltend stabilisierte Wirkstoff-Nanopartikeln
ATE487470T1 (de)	2002-09-11	2010-11-15	Elan Pharma Int Ltd	Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
EP1556091A1 (de) *	2002-10-04	2005-07-27	Elan Pharma International Limited	Gamma-bestrahlung von festen aktivmaterialien in nanopartikularer form
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2504610C (en) *	2002-11-12	2012-02-21	Elan Pharma International Ltd.	Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20050095267A1 (en) *	2002-12-04	2005-05-05	Todd Campbell	Nanoparticle-based controlled release polymer coatings for medical implants
WO2004058216A2 (en) *	2002-12-17	2004-07-15	Elan Pharma International Ltd.	Milling microgram quantities of nanoparticulate candidate compounds
WO2004078162A1 (en) *	2003-01-31	2004-09-16	Elan Pharma International Ltd.	Nanoparticulate topiramate formulations
US20040208833A1 (en) *	2003-02-04	2004-10-21	Elan Pharma International Ltd.	Novel fluticasone formulations
US20100297252A1 (en)	2003-03-03	2010-11-25	Elan Pharma International Ltd.	Nanoparticulate meloxicam formulations
US8512727B2 (en)	2003-03-03	2013-08-20	Alkermes Pharma Ireland Limited	Nanoparticulate meloxicam formulations
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (en)	2003-03-07	2011-07-05	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7140567B1 (en) *	2003-03-11	2006-11-28	Primet Precision Materials, Inc.	Multi-carbide material manufacture and use as grinding media
US7578457B2 (en) *	2003-03-11	2009-08-25	Primet Precision Materials, Inc.	Method for producing fine dehydrided metal particles using grinding media
EP1626742A1 (de) *	2003-05-22	2006-02-22	Elan Pharma International Limited	Sterilisierung von dispersionen von nanopartikulären aktiven stoffen mittels gamma-strahlung
ATE415946T1 (de) *	2003-08-08	2008-12-15	Elan Pharma Int Ltd	Neue metaxalon-zusammensetzungen
MXPA06002455A (es) *	2003-09-02	2006-08-31	Pfizer Prod Inc	Formas de dosificacion de liberacion sostenida de ziprasidona.
EP1686962B9 (de) *	2003-11-05	2012-10-03	Elan Pharma International Limited	Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator
US20050258288A1 (en) *	2003-11-26	2005-11-24	E. I. Du Pont De Nemours And Company	High pressure media milling system and process of forming particles
US7722842B2 (en) *	2003-12-31	2010-05-25	The Ohio State University	Carbon dioxide sequestration using alkaline earth metal-bearing minerals
EP1559419A1 (de) *	2004-01-23	2005-08-03	Fournier Laboratories Ireland Limited	Pharmazeutische Darreichungsformen enthaltend Metformin und ein Fibrat, sowie deren Herstellungsprozesse
BRPI0512829A (pt) *	2004-07-01	2008-04-08	Warner Lambert Co	preparação de composições farmacêuticas contendo nanopartìculas
EP1621200A1 (de) *	2004-07-26	2006-02-01	Fournier Laboratories Ireland Limited	Pharmazeutische Kombinationen enthaltend einen Hemmstoff der Plättchenaggregation und ein Fibrat
DE102004040368B3 (de) *	2004-08-20	2006-02-23	Juhnke, Michael, Dipl.-Ing.	Mahlkörper zur Herstellung feinstkörniger Produkte
US20210299056A9 (en)	2004-10-25	2021-09-30	Varian Medical Systems, Inc.	Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
CN101106972A (zh)	2004-11-16	2008-01-16	伊兰制药国际有限公司	注射用纳米微粒奥氮平制剂
US20090155331A1 (en) *	2005-11-16	2009-06-18	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
CA2590675A1 (en) *	2004-12-15	2006-06-22	Elan Pharma International Ltd.	Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) *	2004-12-22	2006-06-29	Elan Pharma International Ltd.	Nanoparticulate bicalutamide formulations
EP1830902A2 (de) *	2004-12-30	2007-09-12	Cinvention Ag	Kombination aus einem mittel, das ein signal abgibt, implantatmaterial und arzeimittel
EP1835890A2 (de) *	2005-01-06	2007-09-26	Elan Pharma International Limited	Candesartan-nanopartikelformulierungen
CA2591942A1 (en) *	2005-01-13	2006-07-20	Cinvention Ag	Composite materials containing carbon nanoparticles
WO2006077256A1 (en) *	2005-01-24	2006-07-27	Cinvention Ag	Metal containing composite materials
KR20070112164A (ko)	2005-02-15	2007-11-22	엘란 파마 인터내셔널 리미티드	나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
EP1855651A4 (de) *	2005-03-03	2011-06-15	Elan Pharma Int Ltd	Nanopartikelzusammensetzungen heterocyclischer amidderivate
WO2006099121A2 (en) *	2005-03-10	2006-09-21	Elan Pharma International Limited	Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
US20070065374A1 (en) *	2005-03-16	2007-03-22	Elan Pharma International Limited	Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
BRPI0606280A2 (pt) *	2005-03-17	2009-06-09	Elan Pharma Int Ltd	composições de bisfosfonato nanoparticulado
EA200702019A1 (ru) *	2005-03-18	2008-02-28	Синвеншен Аг	Способ изготовления пористых спечённых металлсодержащих материалов
WO2006102494A2 (en) *	2005-03-23	2006-09-28	Elan Pharma International Limited	Nanoparticulate corticosteroid and antihistamine formulations
US20060246141A1 (en) *	2005-04-12	2006-11-02	Elan Pharma International, Limited	Nanoparticulate lipase inhibitor formulations
AU2006235487B2 (en) *	2005-04-12	2011-12-22	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
AU2006235478B2 (en) *	2005-04-12	2011-07-21	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cyclosporine
US20080305161A1 (en) *	2005-04-13	2008-12-11	Pfizer Inc	Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
WO2007070082A1 (en) *	2005-05-10	2007-06-21	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising teprenone
US20110064803A1 (en) *	2005-05-10	2011-03-17	Elan Pharma International Limited.	Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540546A (ja) *	2005-05-10	2008-11-20	エランファーマインターナショナルリミテッド	ナノ粒子クロピドグレル製剤
CA2609296A1 (en) *	2005-05-16	2006-11-16	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising a cephalosporin
US20100028439A1 (en) *	2005-05-23	2010-02-04	Elan Pharma International Limited	Nanoparticulate stabilized anti-hypertensive compositions
EA015102B1 (ru) *	2005-06-03	2011-06-30	Элан Фарма Интернэшнл Лтд.	Препараты наночастиц мезилата иматиниба
WO2006133045A1 (en) *	2005-06-03	2006-12-14	Elan Pharma International, Limited	Nanoparticulate benidipine compositions
CN101262860A (zh) *	2005-06-03	2008-09-10	伊兰制药国际有限公司	纳米微粒对乙酰氨基酚制剂
WO2008073068A1 (en)	2005-06-08	2008-06-19	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cefditoren
ES2335608T3 (es) *	2005-06-09	2010-03-30	Elan Pharma International Limited	Formulaciones de ebistina nanoparticuladas.
US20060280787A1 (en) *	2005-06-14	2006-12-14	Baxter International Inc.	Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2006138202A2 (en) *	2005-06-14	2006-12-28	Baxter International Inc.	Pharmaceutical formulations for minimizing drug-drug interactions
CA2612384A1 (en) *	2005-06-15	2006-12-28	Elan Pharma International, Limited	Nanoparticulate azelnidipine formulations
WO2007027273A1 (en) *	2005-06-20	2007-03-08	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
AU2006265193A1 (en) *	2005-07-01	2007-01-11	Cinvention Ag	Process for the production of porous reticulated composite materials
WO2007003516A2 (en) *	2005-07-01	2007-01-11	Cinvention Ag	Medical devices comprising a reticulated composite material
JP2009500356A (ja) *	2005-07-07	2009-01-08	エランファーマインターナショナルリミテッド	ナノ粒子クラリスロマイシン製剤
US20080213385A1 (en) *	2005-08-10	2008-09-04	Oskar Kalb	Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
GB0516549D0 (en) *	2005-08-12	2005-09-21	Sulaiman Brian	Milling system
JP2009507925A (ja) *	2005-09-13	2009-02-26	エランファーマインターナショナルリミテッド	ナノ粒子タダラフィル製剤
CA2622758A1 (en) *	2005-09-15	2007-03-29	Elan Pharma International, Limited	Nanoparticulate aripiprazole formulations
JP2009511727A (ja) *	2005-10-18	2009-03-19	シンベンションアーゲー	熱硬化粒子及びその製造方法
US20070098803A1 (en)	2005-10-27	2007-05-03	Primet Precision Materials, Inc.	Small particle compositions and associated methods
US20070134341A1 (en) *	2005-11-15	2007-06-14	Kipp James E	Compositions of lipoxygenase inhibitors
US7858609B2 (en) *	2005-11-28	2010-12-28	Marinus Pharmaceuticals	Solid ganaxolone formulations and methods for the making and use thereof
CA2635531C (en)	2005-12-29	2014-06-17	Lexicon Pharmaceutical Inc.	Multicyclic amino acid derivatives and methods of their use
US7649098B2 (en)	2006-02-24	2010-01-19	Lexicon Pharmaceuticals, Inc.	Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) *	2006-02-28	2013-02-05	Alkermes Pharma Ireland Limited	Nanoparticulate carverdilol formulations
EP2001439A2 (de) *	2006-03-07	2008-12-17	Novavax, Inc.	Nanoemulsionen von schlecht löslichen pharmazeutischen aktivbestandteilen und herstellungsverfahren dafür
US11311477B2 (en)	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US10137083B2 (en)	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
EP2012751A4 (de)	2006-03-21	2010-11-24	Morehouse School Of Medicine	Neue nanopartikel zur wirkstofffreisetzung
SG170047A1 (en) *	2006-05-30	2011-04-29	Elan Pharma Int Ltd	Nanoparticulate posaconazole formulations
AU2007264418B2 (en) *	2006-06-30	2012-05-03	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
NZ705763A (en) *	2006-06-30	2016-10-28	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
JP2009543797A (ja) *	2006-07-10	2009-12-10	エランファーマインターナショナル，リミティド	ナノ粒子ソラフェニブ製剤
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
BRPI0717721A2 (pt)	2006-11-28	2013-10-29	Marinus Pharmaceuticals	"partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
UA99270C2 (en)	2006-12-12	2012-08-10	Лексикон Фармасьютикалз, Инк.	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008080047A2 (en) *	2006-12-23	2008-07-03	Baxter International Inc.	Magnetic separation of fine particles from compositions
CN101646402A (zh) *	2007-01-19	2010-02-10	金文申有限公司	用粉末模塑法制成的多孔、不可降解植入物
PL2120878T3 (pl) *	2007-02-09	2015-01-30	Alphapharm Pty Ltd	Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
WO2008104599A1 (en) *	2007-02-28	2008-09-04	Cinvention Ag	High surface cultivation system bag
CA2677699A1 (en) *	2007-02-28	2008-09-04	Cinvention Ag	High surface cultivation system
US20080293814A1 (en) *	2007-05-22	2008-11-27	Deepak Tiwari	Concentrate esmolol
US8722736B2 (en) *	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) *	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US8642062B2 (en)	2007-10-31	2014-02-04	Abbott Cardiovascular Systems Inc.	Implantable device having a slow dissolving polymer
US20090238867A1 (en) *	2007-12-13	2009-09-24	Scott Jenkins	Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
EP2095816A1 (de) *	2008-02-29	2009-09-02	Schlichthaar, Rainer, Dr.	Nanosuspension mit antifungaler Wirkung zur Verabreichung mittels Inhalation mit verbessertem Unreinheitsprofil und erhöhter Sicherheit
AU2009225719A1 (en) *	2008-03-21	2009-09-24	Elan Pharma International Limited	Compositions for site-specific delivery of imatinib and methods of use
US20090311335A1 (en) *	2008-06-12	2009-12-17	Scott Jenkins	Combination of a triptan and an nsaid
TWI447329B (zh)	2008-09-26	2014-08-01	Univ Ohio State	將碳質燃料轉化成無碳能量載體
EP2389159A1 (de)	2009-01-22	2011-11-30	Noramco, Inc.	Verfahren zur herstellung von opioid-partikeln und so hergestellte zusammensetzungen
WO2010096558A1 (en)	2009-02-18	2010-08-26	Eyeon Particle Sciences Llc	Bi-functional co-polymer use for ophthalmic and other topical and local applications
WO2010099508A1 (en)	2009-02-26	2010-09-02	Theraquest Biosciences, Inc.	Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US7828996B1 (en) *	2009-03-27	2010-11-09	Abbott Cardiovascular Systems Inc.	Method for the manufacture of stable, nano-sized particles
SG10201607849TA (en) *	2009-04-24	2016-11-29	Iceutica Pty Ltd	Production of encapsulated nanoparticles at commercial scale
AP3138A (en) *	2009-04-24	2015-02-28	Iceutica Pty Ltd	Production of encapsulated nanoparticles at high volume fractions
KR101580656B1 (ko)	2009-04-24	2015-12-30	아이슈티카 피티와이 리미티드	디클로페낙의 신규 제형
JP5898613B2 (ja) *	2009-04-24	2016-04-06	イシューティカピーティーワイリミテッド	生物学的活性物質の溶解プロファイルを改善するための方法
CN102438594A (zh)	2009-04-24	2012-05-02	伊休蒂卡有限公司	吲哚美辛的新剂型
US20120160944A1 (en) *	2009-04-24	2012-06-28	Aaron Dodd	Method for the production of commercial nanoparticle and micro particle powders
EP3167875A1 (de)	2009-05-27	2017-05-17	Alkermes Pharma Ireland Limited	Reduktion von flockenartiger aggregation in nanoteilchenförmigen meloxicamzusammensetzungen
FR2945950A1 (fr)	2009-05-27	2010-12-03	Elan Pharma Int Ltd	Compositions de nanoparticules anticancereuses et procedes pour les preparer
ES2699077T3 (es)	2009-06-12	2019-02-07	Sunovion Pharmaceuticals Inc	Apomorfina sublingual
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102597173A (zh)	2009-09-08	2012-07-18	俄亥俄州立大学研究基金会	具有原位co2捕集的合成燃料和化学品生产
CN105762386A (zh)	2009-09-08	2016-07-13	俄亥俄州国家创新基金会	具有集成的碳捕集的重整/水裂解和用于发电的电化学系统的集成
CN102711749A (zh)	2009-11-05	2012-10-03	莱西肯医药有限公司	用于癌症治疗的色氨酸羟化酶抑制剂
CN102753168A (zh)	2010-02-10	2012-10-24	莱西肯医药有限公司	用于治疗转移性骨病的色氨酸羟化酶抑制剂
ES2689520T3 (es)	2010-04-23	2018-11-14	Kempharm, Inc.	Formulación terapéutica para reducir los efectos secundarios de fármacos
WO2011146583A2 (en)	2010-05-19	2011-11-24	Elan Pharma International Limited	Nanoparticulate cinacalcet formulations
EP2618818A4 (de)	2010-09-22	2014-10-29	Map Pharmaceuticals Inc	Corticosteroidpartikel und herstellungsverfahren dafür
US10010847B2 (en)	2010-11-08	2018-07-03	Ohio State Innovation Foundation	Circulating fluidized bed with moving bed downcomers and gas sealing between reactors
PT2651357T (pt)	2010-12-16	2020-06-17	Sunovion Pharmaceuticals Inc	Películas sublinguais
MX350838B (es)	2011-02-11	2017-09-18	Grain Proc Corporation *	Composicion de sal.
AU2012253328B2 (en)	2011-05-11	2017-05-25	Ohio State Innovation Foundation	Systems for converting fuel
WO2012155059A1 (en)	2011-05-11	2012-11-15	The Ohio State University	Oxygen carrying materials
PL2748146T3 (pl)	2011-07-22	2017-09-29	Chemocentryx, Inc.	Postać krystaliczna soli sodowej 4-tert-butylo-n-[4-chloro-2-(1-oksy-pirydyno-4-karbonylo)-fenylo]-benzenosulfonamidu
WO2013016156A1 (en)	2011-07-22	2013-01-31	Glaxo Group Limited	Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
SI2751094T1 (sl)	2011-09-01	2018-10-30	Glaxo Group Limited	Nova kristalinična oblika
WO2013059676A1 (en)	2011-10-21	2013-04-25	Subhash Desai	Compositions for reduction of side effects
US9562015B2 (en)	2011-11-17	2017-02-07	The Regents Of The University Of Colorado, A Body	Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
EP2827853A1 (de)	2012-03-22	2015-01-28	Nanotherapeutics, Inc.	Zusammensetzungen und verfahren zur oralen verabreichung eingekapselter diethylentriaminpentaacetat-partikel
WO2013148978A1 (en)	2012-03-30	2013-10-03	Lexicon Pharmaceuticals, Inc.	Methods and compositions for the treatment of necrotizing enterocolitis
JP6360039B2 (ja)	2012-05-03	2018-07-18	カラファーマシューティカルズインコーポレイテッド	複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
ES3055223T3 (en)	2012-05-03	2026-02-10	Alcon Inc	Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
US9461309B2 (en)	2012-08-21	2016-10-04	Kratos LLC	Group IVA functionalized particles and methods of use thereof
EP2888778A1 (de)	2012-08-21	2015-07-01	Kratos LLC	Funktionalisierte gruppe-iva-partikel und verwendungsverfahren dafür
JP6091862B2 (ja) *	2012-11-26	2017-03-08	クリニプロ株式会社	吸入用パウダーの製造方法
JP6033055B2 (ja) *	2012-11-26	2016-11-30	クリニプロ株式会社	吸入用パウダーの製造方法
CA3148322A1 (en)	2013-02-05	2014-08-14	Ohio State Innovation Foundation	Methods for converting fuel into syngas
EP2956138B1 (de)	2013-02-15	2022-06-22	Kala Pharmaceuticals, Inc.	Therapeutische verbindungen und verwendungen davon
MX368903B (es)	2013-02-20	2019-10-21	Kala Pharmaceuticals Inc	Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014152914A1 (en)	2013-03-14	2014-09-25	Ohio State Innovation Foundation	Systems and methods for converting carbonaceous fuels
JP6063090B2 (ja)	2013-06-28	2017-01-18	レクサンファーマシューティカルズインコーポレイテッド	ナノ粒子状組成物およびピペラジン化合物の製剤
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en)	2013-11-01	2016-10-04	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CA2939114A1 (en) *	2014-02-21	2015-08-27	Kratos LLC	Nanosilicon material preparation for functionalized group iva particle frameworks
US20150238915A1 (en)	2014-02-27	2015-08-27	Ohio State Innovation Foundation	Systems and methods for partial or complete oxidation of fuels
WO2015134608A1 (en)	2014-03-05	2015-09-11	Nanotherapeutics, Inc.	Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
SMT202100260T1 (it)	2014-06-25	2021-07-12	Glaxosmithkline Ip Dev Ltd	Sali cristallini di (s)-6-((1-acetilpiperidin-4-il)ammino)-n-(3-(3,4-diidroisochinolin-2(1h)-il)-2-idrossipropil) pirimidin-4-carbossammide.
JP2016035913A (ja)	2014-07-31	2016-03-17	富士フイルム株式会社	全固体二次電池、ならびに、無機固体電解質粒子、固体電解質組成物、電池用電極シートおよび全固体二次電池の製造方法
RU2705376C2 (ru)	2014-08-18	2019-11-07	Алкермес Фарма Айэленд Лимитед	Композиции пролекарства арипипразола
US10016415B2 (en)	2014-08-18	2018-07-10	Alkermes Pharma Ireland Limited	Aripiprazole prodrug compositions
WO2016038519A1 (en)	2014-09-08	2016-03-17	Glaxosmithkline Intellectual Property Development Limited	Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
US10166197B2 (en)	2015-02-13	2019-01-01	St. John's University	Sugar ester nanoparticle stabilizers
EP4578461A3 (de)	2015-04-21	2025-09-03	Sumitomo Pharma America, Inc.	Verfahren zur behandlung von morbus parkinson durch verabreichung von apomorphin an die mundschleimhaut
CA2984421C (en)	2015-05-01	2024-04-09	Cocrystal Pharma, Inc.	Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
AU2016338672A1 (en)	2015-10-16	2018-04-12	Marinus Pharmaceuticals, Inc.	Injectable neurosteroid formulations containing nanoparticles
CA3014788A1 (en)	2016-02-17	2017-08-24	Alkermes Pharma Ireland Limited	Compositions of multiple aripiprazole prodrugs
CA3020406A1 (en)	2016-04-12	2017-10-19	Ohio State Innovation Foundation	Chemical looping syngas production from carbonaceous fuels
BR112019000112A2 (pt)	2016-07-05	2019-04-09	Kratos LLC	partículas do grupo iva micrônicas e sub-micrônicas pré-litiadas passivadas e métodos de preparação das mesmas
EP3481387A4 (de)	2016-08-11	2020-04-08	Ovid Therapeutics Inc	Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
JP6891715B2 (ja) *	2016-08-23	2021-06-18	住友金属鉱山株式会社	試料作製方法および試料分析方法
EP3509423A4 (de)	2016-09-08	2020-05-13	Kala Pharmaceuticals, Inc.	Kristalline formen von therapeutischen verbindungen und verwendungen davon
US10336767B2 (en)	2016-09-08	2019-07-02	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en)	2016-09-08	2020-08-13	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
JP6328860B1 (ja)	2016-09-13	2018-05-23	協和発酵キリン株式会社	医薬組成物
EP3565559A4 (de)	2017-01-09	2020-07-08	Temple University - Of The Commonwealth System of Higher Education	Verfahren und zusammensetzungen zur behandlung von nicht-alkoholischer steatohepatitis
WO2018183909A1 (en)	2017-03-31	2018-10-04	Kratos LLC	Precharged negative electrode material for secondary battery
US11090624B2 (en)	2017-07-31	2021-08-17	Ohio State Innovation Foundation	Reactor system with unequal reactor assembly operating pressures
US10549236B2 (en)	2018-01-29	2020-02-04	Ohio State Innovation Foundation	Systems, methods and materials for NOx decomposition with metal oxide materials
WO2020033500A1 (en)	2018-08-09	2020-02-13	Ohio State Innovation Foundation	Systems, methods and materials for hydrogen sulfide conversion
EP3840754A4 (de)	2018-08-23	2022-09-14	Sunovion Pharmaceuticals Inc.	Säureadditionssalze von apomorphin, pharmazeutische zusammensetzungen damit und verfahren zu deren verwendung
KR102931273B1 (ko) *	2018-11-29	2026-02-27	베즈미아렘 바키프 유니버시테시	점토 첨가제 나노미립자를 얻는 방법
US11266662B2 (en)	2018-12-07	2022-03-08	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020150438A1 (en)	2019-01-17	2020-07-23	Ohio State Innovation Foundation	Systems, methods and materials for stable phase syngas generation
JP7121290B2 (ja) *	2019-02-15	2022-08-18	住友金属鉱山株式会社	試料作製方法および試料分析方法
CN113825568B (zh) *	2019-03-01	2023-09-26	盐野义制药株式会社	减少了异物的纳米粒子组合物及其制造方法
US11453626B2 (en)	2019-04-09	2022-09-27	Ohio State Innovation Foundation	Alkene generation using metal sulfide particles
KR102072968B1 (ko) *	2019-05-28	2020-02-04	주식회사 울트라브이	생분해성 고분자 미세 입자의 제조 방법 및 조직 수복용 생분해성 재료
BR112021024310A2 (pt)	2019-06-05	2022-02-15	Univ Emory	Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
JP7754799B2 (ja)	2019-08-05	2025-10-15	マリナスファーマシューティカルズ，インコーポレイテッド	てんかん重積状態の治療に使用するためのガナキソロン
JPWO2021033633A1 (de)	2019-08-16	2021-02-25
WO2021034888A1 (en)	2019-08-19	2021-02-25	Ohio State Innovation Foundation	Mesoporous support-immobilized metal oxide-based nanoparticles
WO2021046156A1 (en)	2019-09-03	2021-03-11	Ohio State Innovation Foundation	Redox reaction facilitated carbon dioxide capture from flue gas and conversion to carbon monoxide
US20230339880A1 (en)	2019-10-11	2023-10-26	Corbus Pharmaceuticals, Inc.	Compositions of ajulemic acid and uses thereof
WO2021113834A1 (en)	2019-12-06	2021-06-10	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in treating tuberous sclerosis complex
ES2984690T3 (es)	2020-06-26	2024-10-30	Algiax Pharmaceuticals Gmbh	Composición de nanopartículas
WO2022006112A1 (en)	2020-06-29	2022-01-06	Ohio State Innovation Foundation	Systems and methods for high reactant conversion through multiple reactant flow ratio staging

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1807383A (en) *	1928-09-29	1931-05-26	Rubber Surfacers Inc	Grinding method and apparatus
US3104068A (en) *	1959-03-02	1963-09-17	Montedison Spa	Process for preparing ultradispersed pastes and powders of insoluble organic pigments and dyes
US4404346A (en) *	1980-08-05	1983-09-13	Rohm And Haas Company	Production of powdered resin and the powdered resin so produced
US4775393A (en) *	1985-04-11	1988-10-04	The Standard Oil Company	Autogenous attrition grinding
JPS62281953A (ja) *	1986-05-28	1987-12-07	旭光学工業株式会社	骨補填材
US4974368A (en) *	1987-03-19	1990-12-04	Canon Kabushiki Kaisha	Polishing apparatus
US5066486A (en) *	1988-10-14	1991-11-19	Revlon, Inc.	Method for preparing cosmetic products and the products obtained thereby
IT1227626B (it) *	1988-11-28	1991-04-23	Vectorpharma Int	Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5066335A (en) *	1989-05-02	1991-11-19	Ogilvie Mills Ltd.	Glass-like polysaccharide abrasive grit
SU1704783A1 (ru) *	1989-06-23	1992-01-15	Институт Химии Поверхности Ан Усср	Способ получени порошков лекарственных средств
JPH04166246A (ja) *	1990-10-31	1992-06-12	Matsushita Electric Ind Co Ltd	媒体撹拌ミル及び粉砕方法
AU642066B2 (en) *	1991-01-25	1993-10-07	Nanosystems L.L.C.	X-ray contrast compositions useful in medical imaging
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles

1993
- 1993-09-29 AU AU48670/93A patent/AU660852B2/en not_active Expired
- 1993-09-29 NZ NZ248813A patent/NZ248813A/en not_active IP Right Cessation
- 1993-09-30 DE DE69328815T patent/DE69328815T2/de not_active Expired - Lifetime
- 1993-09-30 DK DK93202795T patent/DK0600528T3/da active
- 1993-09-30 CA CA002107400A patent/CA2107400C/en not_active Expired - Lifetime
- 1993-09-30 PT PT93202795T patent/PT600528E/pt unknown
- 1993-09-30 AT AT93202795T patent/ATE193646T1/de active
- 1993-09-30 EP EP93202795A patent/EP0600528B1/de not_active Expired - Lifetime
- 1993-09-30 ES ES93202795T patent/ES2148198T3/es not_active Expired - Lifetime
- 1993-10-01 HU HU9302779A patent/HU210928B/hu unknown
- 1993-10-01 FI FI934320A patent/FI108399B/fi not_active IP Right Cessation
- 1993-10-05 IL IL107191A patent/IL107191A0/xx unknown
- 1993-10-06 TW TW082108254A patent/TW239075B/zh not_active IP Right Cessation
- 1993-10-08 MY MYPI93002059A patent/MY109419A/en unknown
- 1993-10-11 PH PH47059A patent/PH31118A/en unknown
- 1993-10-15 NO NO933719A patent/NO933719L/no unknown
- 1993-10-15 MX MX9306443A patent/MX9306443A/es unknown
- 1993-10-26 CZ CZ932277A patent/CZ284802B6/cs not_active IP Right Cessation
- 1993-10-26 KR KR1019930022264A patent/KR100312798B1/ko not_active Expired - Lifetime
- 1993-11-11 JP JP5282497A patent/JPH06209982A/ja active Pending
- 1993-11-19 SK SK1301-93A patent/SK281078B6/sk not_active IP Right Cessation
- 1993-11-19 RU RU93052890A patent/RU2122405C1/ru active
1994
- 1994-01-12 US US08/180,827 patent/US5518187A/en not_active Expired - Lifetime
2000
- 2000-08-17 GR GR20000401912T patent/GR3034227T3/el unknown
2002
- 2002-08-29 JP JP2002250972A patent/JP2003175341A/ja active Pending

Also Published As

Publication number	Publication date
HU9302779D0 (en)	1993-12-28
DE69328815T2 (de)	2001-02-01
CA2107400C (en)	2007-01-23
TW239075B (de)	1995-01-21
CZ284802B6 (cs)	1999-03-17
JPH06209982A (ja)	1994-08-02
MX9306443A (es)	1994-05-31
MY109419A (en)	1997-01-31
FI108399B (fi)	2002-01-31
GR3034227T3 (en)	2000-12-29
EP0600528A1 (de)	1994-06-08
NO933719L (no)	1994-05-26
NZ248813A (en)	1995-06-27
DE69328815D1 (de)	2000-07-13
PT600528E (pt)	2000-11-30
CZ227793A3 (en)	1994-06-15
NO933719D0 (no)	1993-10-15
AU4867093A (en)	1994-06-09
PH31118A (en)	1998-02-23
KR940010984A (ko)	1994-06-20
EP0600528B1 (de)	2000-06-07
ES2148198T3 (es)	2000-10-16
FI934320A0 (fi)	1993-10-01
IL107191A0 (en)	1994-01-25
SK130193A3 (en)	1994-09-07
FI934320L (fi)	1994-05-26
CA2107400A1 (en)	1994-05-26
US5518187A (en)	1996-05-21
AU660852B2 (en)	1995-07-06
JP2003175341A (ja)	2003-06-24
ATE193646T1 (de)	2000-06-15
HU210928B (en)	1995-09-28
DK0600528T3 (da)	2000-10-16
HUT67644A (en)	1995-04-28
RU2122405C1 (ru)	1998-11-27
KR100312798B1 (ko)	2001-12-28

Legal Events

Date	Code	Title	Description
2014-01-08	MK4A	Patent expired	Expiry date: 20131119

Publication	Publication Date	Title
SK281078B6 (sk)	2000-11-07	Použitie polymérnej živice na mletie liečivej látky alebo diagnostického činidla
EP0760653B1 (de)	2000-09-27	Verfahren zur mahlung von pharmazeutischen substanzen
JP3607294B2 (ja)	2005-01-05	薬剤物質の連続粉砕方法
FI108333B (fi)	2002-01-15	Menetelmõ nanopartikkelikoostumusten valmistamiseksi
DE60133270T2 (de)	2009-04-23	Zerkleinerung mittels mahlkörper
US5718919A (en)	1998-02-17	Nanoparticles containing the R(-)enantiomer of ibuprofen
EP0804165B1 (de)	2001-10-17	Feste arzneimittelform mit polymerem material verteiltem wirkstoff
US6896212B2 (en)	2005-05-24	Method of producing fine solid particles and dispersions
WO1996025181A1 (en)	1996-08-22	Process of preparing lymphography contrast agents